Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting

/PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on...

Related Keywords

United States ,Illinois ,Chicago ,American ,Kyle Begovich ,Hannah Majeski ,Philippe Drouet ,Prnewswire Biotheryx Inc ,American Society Of Clinical Oncology ,Clinical Oncology ,Annual Meeting ,Chief Executive Officer ,Meeting Presentation Details ,Principal Scientist ,Breast Cancer ,Senior Scientist ,Developmental Therapeutics ,Molecularly Targeted Agents ,Tumor Biology ,Biotheryx ,Nc ,